84 related articles for article (PubMed ID: 2405779)
21. Multicenter prospective study of interferon-alpha and conventional chemotherapy versus bone marrow transplantation for newly diagnosed patients with chronic myelogenous leukemia. Kouseisho Leukemia Study Group.
Ohnishi K; Minami S; Ueda T; Nishimura M; Tsubaki K; Takemoto Y; Takeshita A; Sao H; Kageyama S; Ueda R; Ohno R
Int J Hematol; 2000 Aug; 72(2):229-36. PubMed ID: 11039674
[TBL] [Abstract][Full Text] [Related]
22. Imatinib mesylate as treatment for blastic transformation of Philadelphia chromosome positive chronic myelogenous leukemia.
Sureda A; Carrasco M; de Miguel M; Martínez JA; Conde E; Sanz MA; Díaz-Mediavilla J; Sierra J
Haematologica; 2003 Nov; 88(11):1213-20. PubMed ID: 14607749
[TBL] [Abstract][Full Text] [Related]
23. Busulfan versus 32P in polycythaemia vera.
Zittoun R
Drugs Exp Clin Res; 1986; 12(1-3):283-5. PubMed ID: 3525077
[TBL] [Abstract][Full Text] [Related]
24. Bcr-Abl expression levels determine the rate of development of resistance to imatinib mesylate in chronic myeloid leukemia.
Barnes DJ; Palaiologou D; Panousopoulou E; Schultheis B; Yong AS; Wong A; Pattacini L; Goldman JM; Melo JV
Cancer Res; 2005 Oct; 65(19):8912-9. PubMed ID: 16204063
[TBL] [Abstract][Full Text] [Related]
25. Efficacy of alpha interferon and hydroxyurea in late phase refractory myeloproliferative disease.
Litam PP; Landaw SA; Zamkoff KW
Haematologia (Budap); 1994; 26(2):87-90. PubMed ID: 7890266
[TBL] [Abstract][Full Text] [Related]
26. [Chronic myeloid leukemia].
Hehlmann R
Ther Umsch; 1996 Feb; 53(2):82-7. PubMed ID: 8629268
[TBL] [Abstract][Full Text] [Related]
27. Analysis of the impact of imatinib mesylate therapy on the prognosis of patients with Philadelphia chromosome-positive chronic myelogenous leukemia treated with interferon-alpha regimens for early chronic phase.
Kantarjian H; O'Brien S; Cortes J; Shan J; Giles F; Garcia-Manero G; Verstovsek S; Faderl S; Rios MB; Talpaz M
Cancer; 2003 Oct; 98(7):1430-7. PubMed ID: 14508830
[TBL] [Abstract][Full Text] [Related]
28. The management of elderly patients with myeloproliferative disorders.
Tura S
Hematol Oncol; 1993; 11 Suppl 1():39-41. PubMed ID: 8486340
[No Abstract] [Full Text] [Related]
29. [A trial for prolongation of chronic phase of chronic myeloid leukemia--maintenance of leukocyte counts within normal range with busulfan].
Matsuo T; Tomonaga M; Kuriyama K; Jinnai I; Jubashi T; Nonaka H; Kohno T; Tsukasaki K; Atogami S; Itoyama T
Rinsho Ketsueki; 1989 May; 30(5):625-30. PubMed ID: 2795875
[TBL] [Abstract][Full Text] [Related]
30. [Imatinib therapy for patients with chronic myelogenous leukemia].
Usui N
Gan To Kagaku Ryoho; 2005 Mar; 32(3):297-303. PubMed ID: 15791812
[TBL] [Abstract][Full Text] [Related]
31. Interferon alfa versus chemotherapy for chronic myeloid leukemia: a meta-analysis of seven randomized trials: Chronic Myeloid Leukemia Trialists' Collaborative Group.
J Natl Cancer Inst; 1997 Nov; 89(21):1616-20. PubMed ID: 9362160
[TBL] [Abstract][Full Text] [Related]
32. Prolonged chronic phase in chronic myelogenous leukemia after homoharringtonine therapy.
Li YF; Deng ZK; Xuan HB; Zhu JB; Ding BH; Liu XN; Chen BA
Chin Med J (Engl); 2009 Jun; 122(12):1413-7. PubMed ID: 19567163
[TBL] [Abstract][Full Text] [Related]
33. [Antitumor spectra of ranimustine against various human tumors].
Fujimoto S; Tokita H; Nitta K
Gan To Kagaku Ryoho; 1991 Nov; 18(14):2417-22. PubMed ID: 1952961
[TBL] [Abstract][Full Text] [Related]
34. [Natural interferon alpha for chronic myelogenous leukemia in the chronic phase: hematologic, cytogenetic and molecular response].
Takeuchi J; Kawamura M; Sawada U; Ohshima T; Horie T; Horikoshi A; Abe T
Rinsho Ketsueki; 1995 Oct; 36(10):1149-56. PubMed ID: 8531323
[TBL] [Abstract][Full Text] [Related]
35. Sudden blast crisis in patients with Philadelphia chromosome-positive chronic myeloid leukemia who achieved complete cytogenetic remission after imatinib therapy.
Alimena G; Breccia M; Latagliata R; Carmosino I; Russo E; Biondo F; Diverio D; Mancini M; Nanni M; Mandelli F
Cancer; 2006 Sep; 107(5):1008-13. PubMed ID: 16878324
[TBL] [Abstract][Full Text] [Related]
36. Effects of age on prognosis with imatinib mesylate therapy for patients with Philadelphia chromosome-positive chronic myelogenous leukemia.
Cortes J; Talpaz M; O'Brien S; Giles F; Beth Rios M; Shan J; Faderl S; Garcia-Manero G; Ferrajoli A; Wierda W; Kantarjian H
Cancer; 2003 Sep; 98(6):1105-13. PubMed ID: 12973833
[TBL] [Abstract][Full Text] [Related]
37. [Molecular targeted treatment--new treatment strategy for patients with chronic myeloid leukemia].
Usui N
Rinsho Byori; 2004 Feb; 52(2):136-44. PubMed ID: 15027317
[TBL] [Abstract][Full Text] [Related]
38. [Recent progress in therapy for chronic myelogenous leukemia].
Urabe A
Gan To Kagaku Ryoho; 1997 Jul; 24(9):1066-73. PubMed ID: 9239158
[TBL] [Abstract][Full Text] [Related]
39. [Phase II study with methyl-6[[[2-chloroethyl) nitrosoamino] carbonyl] amino]-6-deoxy-alpha-D-glucopyranoside (MCNU) in hematological malignancies].
Masaoka T; Kimura K; Miyazaki T; Sakurada K; Saitoh H; Morioka M; Fujimoto N; Musashi M; Wakui A; Yokoyama M; Kanamaru R; Oguro M; Takagi T; Konda C; Saitoh T; Nakao I; Harashima S; Ohhashi Y; Sakai Y; Sasaki T; Ohno R; Katoh Y; Yamada K; Hirota Y; Takada T; Hoshino A; Ohara K; Kamiya O; Kojima T; Nagata K; Nakamura T; Sasada M; Yonezawa T; Tsubakio T; Kanayama Y; Kitani T; Taniguchi N; Yasunaga K; Okamoto Y; Fujitake H; Ohkubo A; Horiuchi A; Tsubaki K; Takubo T; Shibata H; Kawagoe H; Hirata M; Matsubuchi T; Nagai K; Fujita S
Gan To Kagaku Ryoho; 1983 Jun; 10(6):1518-23. PubMed ID: 6347081
[TBL] [Abstract][Full Text] [Related]
40. [Comparative efficiency of conventional myelosuppressive chemotherapy and therapy including interferon alpha in patients with chronic myeloid leukemia].
Volkova SA; Prytkova MV; Borovkov NN
Klin Med (Mosk); 2004; 82(3):45-50. PubMed ID: 15114775
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
